SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we,...
DALLAS, Sept. 30, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss...
-- Achieves primary endpoint showing a linear relationship between adherence to PoNS Therapy® in Phase 2 and improvement in DGI...
BOWIE, Md., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Epilepsy Foundation announced today it has awarded $200,000 in funding for two...
ROCKLEDGE, Fla., Sept. 30, 2024 (GLOBE NEWSWIRE) -- LUKE Holdings, Inc. (“LUKE”), a trusted leader in healthcare staffing for the...
DURHAM, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract...
CNP-104 demonstrated potential efficacy across multiple immunological and clinical measurements, supporting its continued development as the first disease-modifying treatment for...
Inovalon’s Annual Data-Driven Summit Intersects Healthcare and Technology, Promising to Propel Meaningful Change Across the Care ContinuumBOWIE, Md., Sept. 30,...
SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Adaptive Research, a clinical trial site organization whose mission is to democratize...
Multidisciplinary board members bring expertise in drug discovery, clinical development, computational life science, GPCRs and drug formulationBOSTON, Sept. 30, 2024...
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic...
Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distressStudy results...
MALVERN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
NORCROSS, Ga., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA)...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late...
Boca Raton, Florida, Sept. 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company...
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the...
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio...
